Some members of the Vaccines and Related Biologics Products Advisory Committee worried that a strain change would require new testing that could delay delivery of vaccines for the fall.

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and winter — even as a new Trump administration policy has thrown into question who may be eligible for shots.

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses to the “JN.1” coronavirus lineage.